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OBJECTIVE — Our objective was to perform a quantitative review of prospective studies
examining the association between the metabolic syndrome and incident diabetes.
RESEARCH DESIGN AND METHODS — Using the title terms “diabetes” and “meta-
bolic syndrome” in PubMed, we searched for articles published since 1998.
RESULTS — Based on the results from 16 cohorts, we performed a meta-analysis of estimates
of relative risk (RR) and incident diabetes. The random-effects summary RRs were 5.17 (95% CI
3.99–6.69) for the 1999 World Health Organization deﬁnition (ten cohorts); 4.45 (2.41–8.22)
for the 1999 European Group for the Study of Insulin Resistance deﬁnition (four cohorts); 3.53
(2.84–4.39)forthe2001NationalCholesterolEducationProgramdeﬁnition(thirteencohorts);
5.12 (3.26–8.05) for the 2005 American Heart Association/National Heart, Lung, and Blood
Institute deﬁnition (ﬁve cohorts); and 4.42 (3.30–5.92) for the 2005 International Diabetes
Federationdeﬁnition(ninecohorts).Theﬁxed-effectssummaryRRforthe2004NationalHeart,
Lung, and Blood Institute/American Heart Association deﬁnition was 5.16 (4.43–6.00) (six
cohorts). Higher number of abnormal components was strongly related to incident diabetes.
Comparedwithparticipantswithoutanabnormality,estimatesofRRforthosewithfourormore
abnormal components ranged from 10.88 to 24.4. Limited evidence suggests fasting glucose
alone may be as good as metabolic syndrome for diabetes prediction.
CONCLUSIONS — The metabolic syndrome, however deﬁned, has a stronger association
with incident diabetes than that previously demonstrated for coronary heart disease. Its clinical
value for diabetes prediction remains uncertain.
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S
incemajororganizationssuchasthe
World Health Organization
(WHO), the European Group for
the Study of Insulin Resistance (EGIR),
and the National Cholesterol Education
Program (NCEP) released deﬁnitions of
the metabolic syndrome, it has received a
great deal of attention in the scientiﬁc lit-
erature. Much has been learned about the
many facets of the syndrome, including
its prevalence, incidence, and risks of
leading to the development other condi-
tions such as cardiovascular disease and
diabetes.
Because of the controversy that has
enveloped the concept of the metabolic
syndrome, a thorough understanding of
the association between the syndrome
and diabetes—one of the main risks for
people with the metabolic syndrome—is
critical to furthering the debate about the
syndrome’s scientiﬁc relevance. At the
time of a previous quantitative review,
only a limited number of prospective
studiesofthemetabolicsyndromeandin-
cident diabetes were available (1). Since
that review, additional deﬁnitions of the
syndrome have joined the previous ones,
and the results of more prospective stud-
ies have been published. Therefore, the
main objective of this study was to pro-
videanupdatedquantitativereviewofthe
estimates of relative risk (RR) from pro-
spective studies of the association be-
tween the metabolic syndrome and
incident diabetes. In addition, we sum-
marize other pertinent ﬁndings of these
prospective studies. We also try to place
the results into clinical context by com-
paring metabolic syndrome assessment
with other, potentially simpler methods
of assessing risk of incident diabetes.
RESEARCH DESIGN AND
METHODS—A literature search using
the title terms “metabolic syndrome” and
“diabetes”wasconductedinPubMed.We
limited the search to articles that were
writteninEnglish.BecausetheWHOwas
the ﬁrst to release its deﬁnition, in 1998,
we started our search for articles pub-
lished that year and continued through
April 2008. We reviewed titles and ab-
stracts of the search results and retrieved
promising articles. In addition, we aug-
mentedoursearchwithreviewsoftheref-
erence lists of retrieved articles.
The focus of this article is the pro-
spective association between the meta-
bolic syndrome and incident diabetes in
studies that are more or less population
based. Therefore, we did not include
studies that recruited participants with
speciﬁcconditionssuchascardiovascular
disease. To be included in the analyses,
articleshadtoincludeestimatesofRRand
CIs based on one of the major deﬁnitions
of the metabolic syndrome (2–7). Articles
that presented estimates of RR only in
graphical form were not included in the
quantitative analyses because of the difﬁ-
culty in accurately deriving the estimate
ofRRanditsCI.Whenmultipleestimates
wereavailableforaparticularcohort,only
the estimate that most thoroughly ad-
justed for covariates or that presented es-
timates for men and women combined
was selected. Some studies did not have
all criteria required to deﬁne the meta-
bolic syndrome according to established
criteria, and, consequently, researchers
modiﬁeddeﬁnitionsofthemetabolicsyn-
drome. For example, several studies used
BMI instead of waist circumference (8–
10). Two reviews relating metabolic syn-
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similar RR estimates for studies based on
useofBMI,waistcircumference,orwaist-
to-hip ratio (1,11). Furthermore, one co-
hort did not have concentrations of HDL
cholesterol (12,13). We included these
studies in our summary. In addition, the
WHO deﬁnition technically requires that
participants undergo an oral glucose tol-
erance test (OGTT), have insulin resis-
tance based on a gold-standard technique
(speciﬁcally, the hyperinsulinemic-
euglycemic clamp), and undergo a mea-
surement of microalbuminuria. Most
studies were unable to satisfy these crite-
ria. Therefore, we included studies that
did not conduct an OGTT, used a surro-
gatemeasureofinsulinresistance(suchas
fasting concentration of insulin or ho-
meostasis model assessment of insulin re-
sistance [HOMA-IR]), and did not
measure microalbuminuria. We ab-
stracted the following data elements: lead
author’s name, year of publication, study
name and location, sample size, fol-
low-up time, sex composition and age of
subjects (mean, median, or range), exclu-
sion criteria, metabolic syndrome deﬁni-
tion (including any changes), deﬁnition
of diabetes, number of incident events,
estimate of RR (odds ratio [OR], RR, or
hazard ratio), 95% CI, and variables used
to adjust estimates of RR.
SEs for the estimates of RR were esti-
mated from the CIs. For each study, a
weightwascalculatedastheinverseofthe
variance (1/SE
2). Heterogeneity among
studies was assessed using the Q statistic
(14).Ifnoheterogeneitywaspresent(Pof
Q statistic 0.10), ﬁxed-effects estimates
of RR were calculated according to the
inverse variance method (15). If hetero-
geneity was present (P of Q statistic
0.10), random-effects estimates of RR
werecalculatedusingtheapproachofDer
SimonianandLaird(14).Theinﬂuenceof
single studies on the summary estimates
was examined graphically by checking
how the elimination of each study af-
fected the resulting summary estimate of
RR (16). Evidence for publication bias
was assessed by examining funnel plots
and assessing funnel plot asymmetry
(17). Analyses were conducted using
Stata 9.2.
RESULTS—For our quantitative anal-
yses, we included articles that are based
on 16 cohorts (supplemental table avail-
able in an online appendix at http://
dx.doi.org/10.2337/dc08-0423) (8–
10,12,13,18–32). These 16 cohorts
included over 2,604 incident events
among 42,419 participants, depending
on which of the multiple publications of
the same cohort were included in the
counts.Threecohortsincludedonlymen,
whereas the other 13 included both men
and women. Follow-up times ranged
from 2.3 to 20 years. Two studies were
not included because results were pre-
sentedonlyingraphicalform(33)orcon-
ﬁdence limits were not provided (34).
Ten cohorts yielded estimates of RR
for the association of the metabolic syn-
drome and incident diabetes deﬁned us-
ing the WHO 1999 deﬁnition, and the
random-effects summary RR was 5.17
(95% CI 3.99–6.69) (Fig. 1). Four co-
hortsyieldedestimatesofRRfortheEGIR
1999 deﬁnition, and the random-effects
summaryRRwas4.45(2.41–8.22).Thir-
teen cohorts provided an estimate of RR
for the NCEP 2001 deﬁnition, and the
random-effects summary RR was 3.53
(2.84–4.39). Six cohorts reported esti-
mates of RR for the National Heart, Lung,
and Blood Institute/American Heart As-
sociation (NHLBI/AHA) 2004 deﬁni-
tion, and the ﬁxed-effects summary RR
was 5.16 (4.43–6.00). Five cohorts re-
ported estimated RRs for the AHA/
NHLBI 2005 deﬁnition, and the
random-effects summary RR was 5.12
(3.26–8.05). Nine cohorts produced
estimates of RRs for the International
Diabetes Federation (IDF) 2005 deﬁni-
tion, and the random-effects summary
RR was 4.42 (3.30–5.92). Funnel plot
asymmetry was detected only for the
analysis involving the NCEP 2001 deﬁ-
nition (Egger’s test: P  0.028).
Comparing the summary RRs for the
different deﬁnitions shown above is to
some degree problematic because of dif-
ferencesinstudypopulationsandanalytic
approaches. Thus, a fairer comparison is
between results from sets of studies that
examined the same deﬁnitions and calcu-
lated estimated RRs in the same manner.
Five studies compared the WHO 1999
and NCEP 2001 deﬁnitions
(12,18,23,29,32). The random-effects
summary RR was 4.40 (95% CI 2.87–
6.75)forWHO1999andtheﬁxed-effects
summary RR was 3.12 (2.68–3.64) for
NCEP 2001. Three studies compared the
WHO 1999, NCEP 2001, and IDF 2005
deﬁnitions (23,29,32). The random-
effects summary RR was 5.73 (3.04–
10.79) for the WHO 1999 deﬁnition, and
the ﬁxed-effects summary RRs were 3.50
(2.91–4.22) for the NCEP 2001 deﬁni-
tion and 3.51 (2.83–4.36) for the IDF
2005 deﬁnition. Five studies compared
theNCEP2001andIDF2005deﬁnitions.
The random-effects and ﬁxed-effects
summary RRs were 4.10 (3.13–5.39) and
3.72 (2.97–4.67), respectively
(23,27,29,30,32). Five studies compared
the AHA/NHLBI 2005 and IDF 2005 def-
initions, yielding random-effects sum-
mary RRs of 5.12 (3.26–8.05) and 5.00
(2.84–8.78), respectively (13,25–
27,30). Four studies of the EGIR 1999
and IDF 2005 deﬁnitions produced ran-
dom-effects summary RRs of 4.45 (2.41–
8.22) and 4.33 (2.34–8.01), respectively
(13,26,29,31). Two studies included the
NCEP 2001, AHA/NHLBI 2005, and IDF
2005 deﬁnitions (27,29). Summary RRs
were 6.16 (2.67–14.20) (random-
effects), 4.51 (3.22–6.30) (ﬁxed-effects),
and 4.15 (2.88–5.96) (ﬁxed-effects), re-
spectively. Two studies included the
WHO1999,EGIR1999,andNCEP2001
deﬁnitions (12,29). The ﬁxed-effects
summary RRs were 4.09 (3.25–5.14),
2.78 (2.15–3.58), and 3.13 (2.46–3.99),
respectively. Three studies compared the
NCEP 2001, NHLBI/AHA 2004, and IDF
2005 deﬁnitions (23,27,32). The ﬁxed-
effects summary RRs were 3.95 (3.18–
4.90), 4.44 (3.57–5.52), and 3.77 (3.03–
4.70),respectively.Fourstudiesprovided
results for the WHO 1999 and IDF 2005
deﬁnitions (23,29,31,32). The random-
effects summary RRs were 6.19 (3.85–
9.95) and 3.95 (3.01–5.19), respectively.
Finally,threestudiesproducedinformation
about the WHO 1999 and EGIR 1999 def-
initions (12,29,31). The random-effects
summary RRs were 4.47 (2.79–7.18) and
3.47 (1.81–6.63), respectively.
Sensitivity, speciﬁcity, positive
predictive value, negative predictive
value, and receiver operating
characteristic curve
Estimates of sensitivity and speciﬁcity
were available for ten cohorts
(10,20,21,25,27,29,31–33,35), and esti-
mates of positive and negative predictive
values were available for six cohorts
(25,27,29,31,32,35). Sensitivity ranged
from 0.224 to 0.722, and speciﬁcity
ranged from 0.613 to 0.939 (Table 1).
Positive predictive values ranged from
0.078to0.36andnegativepredictiveval-
ues range from 0.90 to 0.983. Receiver
operating characteristic curves were gen-
erated for six cohorts with the area under
thereceiveroperatingcharacteristiccurve
(aROC), ranging from 0.68 to 0.85
(10,20,23,26,32,35). For studies com-
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among the aROCs were small and gener-
ally nonsigniﬁcant (20,23,26,35).
Number of metabolic syndrome
components
Several studies examined the risk associ-
ated with increasing number of compo-
nents of the metabolic syndrome (Table
2).Inthesestudies,subjectswithzeroab-
normalities formed the reference group.
Threestudiesbasedtheircriteriaonthose
of the NCEP 2001 deﬁnition. The esti-
mated RRs for participants in the West of
Scotland Coronary Prevention Study (8)
were7.26(95%CI:2.25–23.40)forthose
with three abnormalities and 24.4 (7.53–
79.60) for those with four or more abnor-
malities. Estimated RRs for participants
withthreeabnormalitiesandfourormore
abnormalitieswere4.56(2.48–8.78)and
10.88 (5.77–20.50), respectively, in the
British Regional Heart Study (10). In the
Framingham Offspring Study, the esti-
mated RR for participants with three or
more abnormalities was 23.83 5.80–
98.01) among men and 29.69 (9.10–
96.85)amongwomen(22).Furthermore,
atleasttwootherstudiesusingcriterianot
based on one of the major deﬁnitions also
showed substantially elevated estimated
RRs associated with three and four or
more of abnormalities (28,36).
Figure 1—Estimates of RR from prospective studies examining the associations between the metabolic syndrome and incident diabetes.
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studies show that the metabolic syn-
drome,regardlessofhowitisdeﬁned,isa
signiﬁcant predictor of incident diabetes
in many different populations, including
Native Americans, U.S. Hispanics, Mexi-
cans, Turks, Iranians, Mauritians, Chi-
nese, Europeans, and those of European
descent.Althoughconsiderableheteroge-
neity existed among these studies, the av-
erage estimated summary RR of 3.5–5.2
for incident diabetes with any metabolic
syndrome criteria is greater than the asso-
ciation of metabolic syndrome with car-
diovascular events (1.5 to 2.0) (1,11).
These data conﬁrm that the metabolic
syndrome is signiﬁcantly more strongly
associated with risk for incident diabetes,
likely because some of its components (in
particular fasting glucose and waist cir-
cumference) are more strongly associated
with diabetes risk.
Theheterogeneityamongstudiesem-
anates from at least two sources: the ori-
gins of the study population and the
approach in analyzing the study data. For
example, with the NCEP 2001 deﬁnition,
Native Americans cohorts produced a
ﬁxed-effectssummaryRRof1.98(95%CI
1.69–2.32) (18,19), Asian and Mauritius
cohorts produced a ﬁxed-effects sum-
mary RR of 3.53 (2.96–4.20)
(9,12,27,29,32), and North American
Table 1—Sensitivity, speciﬁcity, positive predictive value, negative predictive value, and aROC reported from prospective studies reporting on
the association between the metabolic syndrome and incident diabetes
Reference
number Year Metabolic syndrome deﬁnition Sensitivity Speciﬁcity PPV NPV aROC
33 2002 Modiﬁed WHO 1998, WHR 0.91 0.67 0.80
Modiﬁed WHO 1998, WC 94 cm 0.57 0.83
NCEP 2001, WC 102 cm 0.41 0.90
NCEP 2001, WC 94 cm 0.49 0.84
20 2003 NCEP 2001 0.528 0.849 0.308 0.934 0.776
Modiﬁed WHO 1999 0.428 0.872 0.304 0.921 0.762
21 2004 NCEP 2001 (SAHS) 0.662 0.722
NCEP 2001 (MCDS) 0.624 0.613
35 2005 NCEP 2001 0.50 0.82 0.36 0.90 0.75
NCEP 2001, FPG 100–125 mg/dl 0.64 0.74 0.32 0.91 0.75
NCEP 2001, augmented 0.81 0.61 0.29 0.94 0.78
23 2005 NCEP 2001 0.69
WHO 1999 0.68
IDF 2005 0.68
10 2005 Number of abnormalities over 10 years 0.626 0.747 0.72
Number of abnormalities over 20 years 0.539 0.757 0.70
25 2007 IDF 2005 0.703 0.746
AHA/NHLBI 2005 0.611 0.831
Modiﬁed WHO 1999 0.549 0.866
26 2007 AHA/NHLBI 2005 0.82–0.85
IDF 2005 0.82–0.85
EGIR 1999 0.78–0.84
27 2007 NCEP 2001 0.258 0.939 0.246 0.943
NHLBI/AHA 2004 0.342 0.919 0.244 0.948
AHA/NHLBI 2005 0.419 0.875 0.205 0.951
IDF 2005 0.317 0.902 0.199 0.945
29 2007 Modiﬁed WHO 1999 0.421 0.882 0.268 0.937
NCEP 2001 0.389 0.850 0.208 0.932
EGIR 1999 0.224 0.921 0.224 0.921
IDF 2005 0.240 0.907 0.209 0.921
IDF 2005 with WHO obesity 0.464 0.838 0.226 0.939
NCEP 2001 with WHO obesity 0.553 0.793 0.214 0.946
IDF 2005 with reduced WC 0.498 0.792 0.196 0.939
31 2008 WHO 1999 0.564 0.829 0.115 0.980
NCEP 2004 0.622 0.764 0.099 0.981
EGIR 1999 0.464 0.859 0.116 0.976
IDF 2005 0.649 0.713 0.082 0.981
32 2008 Modiﬁed WHO 1999 0.5479 0.9081 0.1973 0.9799
NCEP 2001 0.6075 0.7327 0.0863 0.9782 0.72
IDF 2005 0.7219 0.6468 0.0779 0.9824
NHLBI/AHA 2004 0.7043 0.6999 0.0889 0.9827 0.74
ADA, American Diabetes Association; FPG, fasting plasma glucose; MCDS, Mexico City Diabetes Study; NPV, negative predictive value; PPV, positive predictive
value; SAHS, San Antonio Heart Study; WC, waist circumference; WHR, waist-to-hip ratio.
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dom-effects summary RR of 4.13 (3.16–
5.40) (8,10,20,21,23,30). The variables
used to adjust estimated RRs varied con-
siderably among studies, with some ad-
justing for nothing, others for multiple
factors,andotherspotentiallyoveradjust-
ing with use of, for example, OGTTs.
Although a variety of diabetes risk
prediction models exist, some not requir-
ing any laboratory measures, three direct
comparisons of the predictive ability of
the metabolic syndrome and a single dia-
betes risk score, the Diabetes Risk Score,
have been conducted (21,29,31). This
prediction model includes age, sex, eth-
nicity, fasting glucose, systolic blood
pressure,HDLcholesterol,BMI,andfam-
ily history of diabetes (37). Thus, four
components of the metabolic syndrome
aspertheNCEP2001deﬁnitionandsub-
sequent revisions (with BMI in lieu of
waist circumference) are represented in
continuous form in this model. Both in
the San Antonio Heart Study and the
Mexico City Diabetes Study, the sensitiv-
ity of the Diabetes Risk Score was signiﬁ-
cantly larger than that of metabolic
syndrome diagnosis at a given speciﬁcity
(21). In a study conducted in Mauritius,
Cameron et al. concluded that the Diabe-
tes Predicting Model provided somewhat
better prediction than the metabolic syn-
drome (29). Using data of the AusDiab
study, Cameron et al. reached a similar
conclusion (31).
Furthermore, the concept of risk
scores using routinely available or easily
collectabledatahasemergedasanappeal-
ing tool for predicting both undiagnosed
prevalent diabetes and the risk for future
incident diabetes. The Finnish Diabetes
Risk Score (FINDRISC)—using categori-
cal variables for age, BMI, waist circum-
ference, history of antihypertensive drugs
or high blood glucose, physical activity,
and daily consumption of fruit, berries,
and vegetables—achieved an aROC be-
tween 0.85 and 0.87 for 10-year incident
diabetes (38), exceeding the aROC re-
ported in all the metabolic syndrome
studies reporting these data (Table 2).
However, results from the AusDiab study
showed that a modiﬁed version of
FINDRISC (score 10) had a worse pos-
itive predictive value and speciﬁcity at a
comparablesensitivitythanthemetabolic
syndrome using the NCEP 2001 and IDF
2005 deﬁnitions (31). Similarly, the re-
cent German Diabetes Risk Score (com-
prising age, height, waist circumference,
history of hypertension, physical activity,
smoking, and dietary factors) has re-
ported an aROC for incident diabetes of
between 0.82 and 0.84 (39).
Of the components of the metabolic
syndrome, impaired fasting glucose is
generally thought to be the strongest pre-
dictor of diabetes (8,12,13,22,27,29,
31,40). Like that of Cameron et al., most
studies reported that concentrations of
fasting glucose provided similar or, as in
the AusDiab study, better prediction of
diabetes than metabolic syndrome diag-
nosis (31). However, Lorenzo et al. (25)
showedthatthemetabolicsyndromepro-
vided additional prediction beyond that
provided by impaired fasting glucose
alone in the San Antonio Heart Study.
Little research has been conducted
examining the predictive ability of the
various combinations of metabolic syn-
drome components in deﬁnitions such as
the NCEP 2001, NHLBI/AHA 2004, and
AHA/NHLBI 2005. One possible reason
for this is that many studies have not had
sufﬁcient incident events of diabetes to
evaluate the many combinations. For ex-
ample, the NCEP 2001 deﬁnition and the
two subsequent updates yield 16 combi-
nations of three or more cardiometabolic
abnormalities. Using data from the Fra-
mingham Offspring Study, Wilson et al.
(22) did examine a number of combina-
tions of the ﬁve NHLBI/AHA 2004 com-
ponents and concluded that the RRs of
combinations of three abnormalities were
not larger than combinations of two fac-
tors or, indeed, elevated fasting glucose
alone.
Another issue that has received little
attention is whether the metabolic syn-
dromerepresentsmorethanthesumofits
parts. Cameron et al. (29) found that only
the WHO 1999 deﬁnition—not the
NCEP 2001, EGIR 1999, or IDF 2005
deﬁnitions—signiﬁcantly added to the
prediction of incident diabetes in models
that included the individual components
of the metabolic syndrome. Using data
from the West of Scotland Coronary Pre-
vention Study, Sattar et al. (8) concluded
that the metabolic syndrome was not a
signiﬁcant predictor of incident diabetes
once its components were accounted for.
A number of researchers have exam-
ined the effect of changing aspects of the
deﬁnition of the metabolic syndrome on
the predictive ability of the syndrome for
diabetes. Lowering waist circumference
or glucose thresholds generally increased
theprevalenceofthemetabolicsyndrome
and the sensitivity but at the expense of
speciﬁcity (8,32,33,35).
Some of the most extensive efforts at
improving the predictive ability of the
metabolic syndrome, starting with the
NCEP 2001 deﬁnition, were conducted
by Hanley et al. (23) using data from the
Insulin Resistance Atherosclerosis Study.
To some degree, the numerous changes
that the authors tested affected the prev-
alence of the metabolic syndrome, the
ORs for incident diabetes, and the popu-
lation-attributable risk. The lowest
aROCs of 0.66 were observed for deﬁni-
tions that required fasting plasma glucose
or elevated waist circumference as man-
datory components. The highest aROC of
0.72 was observed for a deﬁnition that
included the insulin sensitivity index as a
sixth component.
A couple of investigations also com-
pared the predictive ability of the meta-
bolic syndrome with that of individual
components of the metabolic syndrome
or ones closely related to it. In the San
Antonio Heart Study, Lorenzo et al. (20)
reported that the aROC for NCEP 2001
was similar to that for the 2-h glucose
Table2—EstimatesofOR,RR,orhazardratio(HR)usingzeroabnormalitiesasthereference
category from prospective studies reporting on the association between the metabolic syn-
drome and incident diabetes
Reference
number Year
Number of
criteria OR/RR/HR
95% Lower
limit
95% Upper
limit
36 2002 3 9.37 2.22 39.59
4 33.67 7.93 142.96
8 2003 3 7.26 2.25 23.4
4 24.4 7.53 79.6
22 2005 (Men) 3 23.83 5.80 98.01
22 2005 (Women) 3 29.69 9.10 96.85
10 2005 3 4.56 2.48 8.78
4 10.88 5.77 20.50
28 2007 3 7.05
4 13.39 4.26 42.08
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predictive ability of impaired glucose tol-
erance, quantitative insulin sensitivity
check index, insulin sensitivity, the ratio
of concentrations of triglycerides to HDL
cholesterol, hypertriglyceridemic waist,
and concentrations of C-reactive protein
compared with NCEP 2001, WHO 1999,
and IDF 2005 deﬁnitions of metabolic
syndrome.Theprevalenceofthesecondi-
tions ranged from a low of 18.4% for the
hypertriglyceridemic waist to a high of
69.6% for a concentration of C-reactive
protein1mg/l.AconcentrationofC-re-
active protein 3 mg/l yielded the lowest
OR for incident diabetes (1.83 [95% CI:
1.23–2.74]), aROC (0.60), and popula-
tion-attributable risk (19.4%), whereas
impaired glucose tolerance yielded the
highest OR (5.42 [3.60–8.17]), aROC
(0.72), and population-attributable risk
(58.47%).
Our study illustrates that the meta-
bolicsyndromeisafairlystrongpredictor
of incident diabetes in many populations
andthatitpredictsdiabetesmorestrongly
than it predicts coronary heart disease
events. However, whether the metabolic
syndrome was ever intended to be more
strongly predictive of diabetes than car-
diovascular disease is not entirely clear.
Additional comparisons of the metabolic
syndrome to simple, readily available
non–laboratory-based questionnaires are
needed because questionnaires appear
better placed as initial screening tools to
identifyhigh-riskindividuals,whosesub-
sequentevaluationwouldincorporatethe
resultsfrombloodtests.Moreover,onthe
balanceofcurrentbutlimitedevidence,it
appearsthatthemetabolicsyndromemay
not add to the prediction of incident dia-
betes beyond its components, in particu-
lar impaired fasting glucose, although
moredataareneededtoconﬁrmthis.The
most successful attempts to improve the
predictive ability of the metabolic syn-
drome appear to have revolved around
creating more of a continuous scale from
its components, emphasizing loss of
power from a dichotomous use of data.
Current evidence casts substantial doubt
on the clinical value of diagnosing the
metabolic syndrome to identify those at
elevated risk for diabetes.
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